Bladder cancer invasion predictability based on preoperative neutrophil-lymphocyte ratio

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6601-6605

  Kaynar, Mehmet ^a   Yıldırım, Mehmet Erol ^b   Badem, Hüseyin ^b   Çaviş, Mücahit ^b   Tekinarslan, Erdem ^c   İstanbulluoğlu, Mustafa Okan ^d   Karataş, Ömer Faruk ^b   Çimentepe, Ersin ^b  

^a SELCUK UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b TURGUT OZAL UNIVERSITY   (Turkey)

^c Konya Education and Research Hospital   (Turkey)

^d MEVLANA UNIVERSITY   (Turkey)

Author keywords

Bladder cancer; Neutrophil lymphocyte ratio; Platelet lymphocyte ratio; Tumor invasiveness

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CELL COUNT; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; NEUTROPHIL; NEUTROPHIL LYMPHOCYTE RATIO; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; THROMBOCYTE; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEUTROPHILS; PREOPERATIVE PERIOD; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 84904972217     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1889-x     Document Type: Article

References (26)

1. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T el al. Guidelines on muscle-invasive and metastatic bladder cancer. EAU Guideline 2013;1-82.
2. Sobin LH, Gospodariwicz M, Wittekind C, editors. TNM classification of malignant tumors. UICC International Union Against Cancer, ed. 7. Hoboken: Wiley-Blackwell; 2009. p. 262-5.
3. Van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005;47(6):736-48. (Pubitemid 40745338)
4. Zahorec R. Ratio of neutrophil to lymphocyte counts - rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5-14.
5. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149-63.
6. Clarke SJ, Chua W, Moore M, Kao S, Phan V, Tan C, et al. Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther. 2011;90(3):475-8.
7. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophillymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181-4. (Pubitemid 41254421)
8. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pretreatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58(1):15-23.
9. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010;16(23):5805-13.
10. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol. 2010;184(3):873-8.
11. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639-53.
12. De Boer EC, De Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, De Groot ER, et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother. 1992;34(5):306-12.
13. Taniguchi K, Koga S, Nishikido M, Yamashita S, Sakuragi T, Kanetake H, et al. Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer. Clin Exp Immunol. 1999;115(1):131-5. (Pubitemid 29030375)
14. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99.
15. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7. (Pubitemid 36019639)
16. Tachibana M, Miyakawa A, Tazaki H, Nakamura K, Kubo A, Hata J, et al. Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res. 1995;55(15):3438-43.
17. Gondo T, Nakashima J, Ohno Y, Choichiro O, Horiguchi Y, Namiki K, et al. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology. 2012;79(5):1085-91.
18. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013;190(6):1999-2004.
19. Dalpiaz O, Ehrlich GC, Mannweiler S, Hernández JM, Gerger A, Stojakovic T, et al. Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. BJU Int. 2013. doi:10.1111/bju.12441.
20. Bircan S, Candir O, Kapucuoglu N. The effect of tumor invasion patterns on pathologic stage of bladder urothelial carcinomas. Pathol Oncol Res. 2005;11(2):87-91. (Pubitemid 41039443)
21. Can C, Baseskioglu B, Yilmaz M, Colak E, Ozen A, Yenilmez A. Pretreatment parameters obtained from peripheral blood sample predicts invasiveness of bladder carcinoma. Urol Int. 2012;89(4):468-72.
22. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012;23(4):265-73.
23. Azuma T, Matayoshi Y, Odani K, Sato Y, Sato Y, Nagase Y, et al. Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma. Clin Genitourin Cancer. 2013;11(3):337-41.
24. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218-30.
25. Schiffer E, Vlahou A, Petrolekas A, Stravodimos K, Tauber R, Geschwend JE, et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res. 2009;15(15):4935-43.
26. Thrasher JB, Frazier HA, Robertson JE, Dodge RK, Paulson DF. Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer. 1994;73(6):1708-15. (Pubitemid 24085274)